$CEAD
CEA Industries Inc. Stock $cead

$cead Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224045783 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$390.8K
YoY Change		-57.22%
Cost Of Revenue		$461.0K
YoY Change		-54.7%
Gross Profit		-$70.15K
YoY Change		-32.59%
Gross Profit Margin		-17.95%
Selling, General & Admin		$676.1K
YoY Change		-0.79%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$4.710K
YoY Change		-62.26%
% of Gross Profit
Operating Expenses		$676.5K
YoY Change		-3.77%
Operating Profit		-$746.7K
YoY Change		-7.48%
Interest Expense		$6.270K
YoY Change		-22.01%
% of Operating Profit
Other Income/Expense, Net		$6.269K
YoY Change		-22.06%
Pretax Income		-$740.4K
YoY Change		-7.34%
Income Tax
% Of Pretax Income
Net Earnings		-$740.4K
YoY Change		-7.34%
Net Earnings / Revenue		-189.45%
Basic Earnings Per Share		-$0.94
Diluted Earnings Per Share		-$0.94
COMMON SHARES
Basic Shares Outstanding	791.6K shares	791.6K shares
Diluted Shares Outstanding		791.6K shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$10.30M
YoY Change		-22.84%
Cash & Equivalents		$10.30M
Short-Term Investments
Other Short-Term Assets		$421.3K
YoY Change		30.12%
Inventory		$24.68K
Prepaid Expenses
Receivables		$71.24K
Other Receivables		$0.00
Total Short-Term Assets		$11.04M
YoY Change		-22.57%
LONG-TERM ASSETS
Property, Plant & Equipment		$9.605K
YoY Change		-79.0%
Goodwill
YoY Change
Intangibles		$1.830K
YoY Change
Long-Term Investments
YoY Change
Other Assets		$14.75K
YoY Change		0.0%
Total Long-Term Assets		$299.6K
YoY Change		-32.76%
TOTAL ASSETS
Total Short-Term Assets		$11.04M
Total Long-Term Assets		$299.6K
Total Assets		$11.34M
YoY Change		-22.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$162.5K
YoY Change		-0.92%
Accrued Expenses		$334.8K
YoY Change		-37.1%
Deferred Revenue		$469.0K
YoY Change		-1.25%
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$966.2K
YoY Change		-17.49%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities		$166.7K
YoY Change		-42.53%
Total Long-Term Liabilities		$166.7K
YoY Change		-42.53%
TOTAL LIABILITIES
Total Short-Term Liabilities		$966.2K
Total Long-Term Liabilities		$166.7K
Total Liabilities		$1.133M
YoY Change		-22.46%
SHAREHOLDERS EQUITY
Retained Earnings		-$39.32M
YoY Change		8.6%
Common Stock		$8.00
YoY Change		-90.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$10.20M
YoY Change
Total Liabilities & Shareholders Equity		$11.34M
YoY Change		-22.88%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$740.4K
YoY Change		-7.34%
Depreciation, Depletion And Amortization		$4.710K
YoY Change		-62.26%
Cash From Operating Activities		-$1.030M
YoY Change		20.56%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities		-1.030M
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash		-1.030M
YoY Change		20.59%
FREE CASH FLOW
Cash From Operating Activities		-$1.030M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80027
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	76487	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2089328	usd
	us-gaap	Operating Expenses OperatingExpenses	2102958	usd
	us-gaap	Operating Expenses OperatingExpenses	2785757	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-746672	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-807062	usd
CY2024Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	229535	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	24680	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6659858	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	460970	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	1017634	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001482541
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80027
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	71240	usd
CY2024Q3	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	224414	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	24680	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	421260	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	11036753	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9605	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1830	usd
CY2024Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	14747	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	273375	usd
CY2024Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	299557	usd
CY2024Q3	us-gaap	Assets Assets	11336310	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	364154	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	468963	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	133127	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	966244	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	166685	usd
CY2024Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	166685	usd
CY2024Q3	us-gaap	Liabilities Liabilities	1132929	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39317597	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	10203381	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11336310	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	390817	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	913571	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2386023	usd
	us-gaap	Cost Of Revenue CostOfRevenue	2430751	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	-70153	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	-104063	usd
	us-gaap	Gross Profit GrossProfit	-44728	usd
CY2024Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	450	usd
CY2023Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	21551	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	13630	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	676069	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	681448	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	676519	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	702999	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2147686	usd
CY2024Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	6269	usd
CY2023Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	8043	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	20381	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6269	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8043	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	20381	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-740403	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2127305	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-740403	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-799019	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2127305	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	CEAD	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	CEAD	Options Issued For Accrued Equity Compensation Liability OptionsIssuedForAccruedEquityCompensationLiability		usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense		usd
CY2023Q4	CEAD	Class Of Warrant Or Right Outstanding Aggregate Intrinsic Value ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	CEAD	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableGranted		shares
	CEAD	Class Of Warrant Or Right Weighted Average Exercise Price Granted ClassOfWarrantOrRightWeightedAverageExercisePriceGranted
	CEAD	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Granted Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerms
	CEAD	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Granted SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	CEAD	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableExercised		shares
	CEAD	Class Of Warrant Or Right Weighted Average Exercise Price Exercised ClassOfWarrantOrRightWeightedAverageExercisePriceExercised
	CEAD	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercised Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisedWeightedAverageRemainingContractualTerms
	CEAD	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised		usd
	CEAD	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Expired Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExpiredWeightedAverageRemainingContractualTerms
	CEAD	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Expirations SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpirations		usd
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		usd
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41266
	dei	Entity Registrant Name EntityRegistrantName	CEA INDUSTRIES INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-3911608
	dei	Entity Address Address Line1 EntityAddressAddressLine1	385 South Pierce Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite C
	dei	Entity Address City Or Town EntityAddressCityOrTown	Louisville
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
	dei	City Area Code CityAreaCode	(303)
	dei	Local Phone Number LocalPhoneNumber	993-5271
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	791580	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10295159	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12508251	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18655	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	224414	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	296404	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	313115	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	13360839	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38558	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1830	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	14747	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	356109	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	411244	usd
CY2023Q4	us-gaap	Assets Assets	13772083	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	624724	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	499800	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	126724	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1251248	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	259627	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	259627	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1510875	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	791580	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	791580	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	673090	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	673090	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	8	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	7	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	49520970	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	49451493	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-37190292	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	12261208	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13772083	usd
	us-gaap	Cost Of Revenue CostOfRevenue	5831953	usd
	us-gaap	Gross Profit GrossProfit	827905	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	256965	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2452305	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1957852	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7778	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	26042	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	33820	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-799019	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1924032	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1924032	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.94
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.94
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.19
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.92
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.92
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.86
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.86
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	791580	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	791580	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	673031	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	673031	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	729333	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	729333	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	672904	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	672904	shares
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	10943784	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-740403	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	10203381	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	12261208	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	-5522	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	75000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2127305	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	10203381	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	14022392	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	15166	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-799019	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	13238539	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14895175	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14895175	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	166080	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	101316	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1924032	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	13238539	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	13238539	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2127305	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1924032	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16328	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	22476	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	69478	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	177427	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-40094	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-2056	usd
	us-gaap	Inventory Write Down InventoryWriteDown	36839	usd
	us-gaap	Inventory Write Down InventoryWriteDown	111123	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-12625	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-100	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	82734	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	79705	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	12490	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	267842	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-234885	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	77808	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	108147	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-1166170	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-260570	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-635373	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-30836	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3863683	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-86539	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-80716	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2213092	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5294509	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	200	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	200	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2213092	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5294309	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12508251	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18637114	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10295159	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13342805	usd
	CEAD	Options Issued For Accrued Equity Compensation Liability OptionsIssuedForAccruedEquityCompensationLiability	89970	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21711000	usd
CY2024Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	one-for-twelve
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zGm1VvbGwFM" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 30.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zS1o9EJQzHX6">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management makes estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and that affect the reported amounts of revenue and expenses during the reporting period. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Key estimates include: allocation of transaction prices to performance obligations under contracts with customers, standalone selling prices, timing of expected revenue recognition on remaining performance obligations under contracts with customers, valuation of intangible assets as it applies to impairment analysis, valuation of equity-based compensation, valuation of deferred tax assets and liabilities, warranty accruals, inventory allowances, and legal contingencies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10295000	usd
CY2024Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	10045000	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	85000	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	125000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-40094	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-2056	usd
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	643906	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	666069	shares
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	390817	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	913571	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2386023	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6659858	usd
CY2024Q3	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	224414	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	1436	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	1436	usd
CY2024Q3	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	224414	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	224414	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	468963	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	499800	usd
CY2024Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	116610	usd
CY2023Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	12461	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	3911083	usd
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	352000	usd
CY2023Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	548000	usd
CY2024Q3	CEAD	Remaining Performance Obligations Related To Partial Equipment Paid Contracts RemainingPerformanceObligationsRelatedToPartialEquipmentPaidContracts	352000	usd
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	352000	usd
	us-gaap	Standard Product Warranty Description StandardProductWarrantyDescription	The Company assesses the historical warranty claims on its manufactured products and, since 2016, warranty claims have been approximately 1% of annual revenue generated on these products. Based on the Company’s warranty policy, an accrual is established at 1% of the trailing 18 months revenue.
CY2024Q3	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	53527	usd
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	191338	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15166	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	69478	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	177428	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_zllsg5pc7Fpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zcjjAqIT1vx4">Concentrations</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two customers accounted for <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zEyzYv7vRtG5" title="Concentration risk percentage">43</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zWtRGdxe8Sq7" title="Concentration risk percentage">39</span>% of the Company’s revenue, respectively, for the three months ended September 30, 2024. One customer accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zOcLZeblSlDd" title="Concentration risk percentage">54</span>% of the Company’s revenue for the nine months ended September 30, 2024. Four customers accounted for <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z3YkR3kDHTuf" title="Concentration risk percentage">29</span>%, <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zbDXBHsxGDC8" title="Concentration risk percentage">19</span>%, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zbE8C86abUf2" title="Concentration risk percentage">16</span>%, and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFourMember_zKVqi05WNByl" title="Concentration risk percentage">12</span>% of the Company’s revenue for the three months ended September 30, 2023. Three customers accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_znsFPXhEbFGi" title="Concentration risk percentage">38</span>%, <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zUWiRFrDJPIj" title="Concentration risk percentage">20</span>% and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zYvNDkrFIX74" title="Concentration risk percentage">12</span>% of the Company’s revenue for the nine months ended September 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three customers accounted for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z4AYyADwljbh" title="Concentration risk percentage">55</span>%, <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zLdIVxQhcyci" title="Concentration risk percentage">34</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zOWlZ9N4LYV1" title="Concentration risk percentage">11</span>% of the Company’s accounts receivable, respectively, as of September 30, 2024. Three customers accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zejE4oUNjBU" title="Concentration risk percentage">59</span>%, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zMQMDAiec0fi" title="Concentration risk percentage">29</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zQ6ekmjXXjRd" title="Concentration risk percentage">12</span>% of the Company’s accounts receivable, respectively, as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	273375	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	133127	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	166685	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0363	pure
	us-gaap	Operating Lease Payments OperatingLeasePayments	96003	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	32641	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	132503	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	136473	usd
CY2024Q3	CEAD	Lessee Operating Lease Liability Payments Due After Year Two LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo	11654	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	313271	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13459	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	299812	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	141393	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	366844	usd
CY2024Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	112822	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	122258	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	192698	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	296404	usd
	us-gaap	Cost Of Goods And Services Sold Overhead CostOfGoodsAndServicesSoldOverhead	8155	usd
CY2023	us-gaap	Cost Of Goods And Services Sold Overhead CostOfGoodsAndServicesSoldOverhead	13679	usd
CY2024Q3	CEAD	Prepaid Inventory Expenses PrepaidInventoryExpenses	128000	usd
CY2023Q4	CEAD	Prepaid Inventory Expenses PrepaidInventoryExpenses	6000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	264511	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	290994	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	254906	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	252436	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9605	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38558	usd
	us-gaap	Depreciation Depreciation	16328	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	162528	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	183359	usd
CY2024Q3	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	2050	usd
CY2023Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	1710	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	115674	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	189829	usd
CY2024Q3	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	53527	usd
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	191338	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	30375	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	58488	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	364154	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	624724	usd
CY2023Q4	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	1049280	usd
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	791580	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	791580	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	one-for-twelve
CY2024Q2	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	107126	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	791580	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	791580	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	673090	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	673090	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	635314	shares
CY2023Q4	CEAD	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	635314	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	61.72
	CEAD	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerms	P37M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	17529	shares
	CEAD	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableExpirations	-17529	shares
	CEAD	Class Of Warrant Or Right Weighted Average Exercise Price Expired ClassOfWarrantOrRightWeightedAverageExercisePriceExpired	114.34
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	617785	shares
CY2024Q3	CEAD	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	617785	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	60.23
	CEAD	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm	P29M
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	617785	shares
CY2024Q3	CEAD	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	617785	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P29M
CY2024Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	30967000	usd
CY2024Q3	CEAD	Net Operating Loss Carry Forward Expected To Expire Amount NetOperatingLossCarryForwardExpectedToExpireAmount	11196000	usd
	CEAD	Net Operating Loss Expiration Term NetOperatingLossExpirationTerm	2034 through 2037
CY2024Q3	CEAD	Nols Usage Against Taxable Income Percentage NolsUsageAgainstTaxableIncomePercentage	0.80	pure
	CEAD	Nols Carryforwards Term Description NolsCarryforwardsTermDescription	three-year period
	us-gaap	Payments For Commissions PaymentsForCommissions	6763	usd
	us-gaap	Payments For Commissions PaymentsForCommissions	18273	usd
	us-gaap	Payments For Deposits PaymentsForDeposits	14035	usd

Files In Submission

Name	View Source	Status
0001493152-24-045783-index-headers.html	Edgar Link	pending
0001493152-24-045783-index.html	Edgar Link	pending
0001493152-24-045783.txt	Edgar Link	pending
0001493152-24-045783-xbrl.zip	Edgar Link	pending
cead-20240930.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
cead-20240930_cal.xml	Edgar Link	unprocessable
cead-20240930_def.xml	Edgar Link	unprocessable
cead-20240930_lab.xml	Edgar Link	unprocessable
cead-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CEAD
CEA Industries Inc. Stock $cead

2024 Q4 Form 10-Q Financial Statement

#000149315224045783 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CEAD CEA Industries Inc. Stock $cead

2024 Q4 Form 10-Q Financial Statement

#000149315224045783 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CEAD
CEA Industries Inc. Stock $cead